Management of non-insulin-dependent diabetes mellitus: Defining the role of metformin

Disease Management and Health Outcomes

Volumn 1, Issue 1, 1997, Pages 49-59

  Balfour, Julia A ^a   Clissold, Stephen P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002020756     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199701010-00008     Document Type: Article

References (48)

1. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995 May; 49: 721-49
2. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet 1994; 343: 95-100
3. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94
4. DeFronzo RA. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-87
5. Songer TJ, Zimmet PZ. Epidemiology of type II diabetes. An international perspective. PharmacoEconomics 1995; 8 Suppl. 1: 1-11
6. Anonymous. The pharmacological treatment of hyperslycemia in NIDDM. Diabetes Care 1996; 19 Suppl. 1: S54-61
7. Harris MI. Diabetes in America (2nd edition). NIH Publication No. 95-1468, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, 1995
8. Dowse GK, Zimmet PZ, Gareeboo H, et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole and Chinese Mauritians. Diabetes Care 1991; 14 (4): 271-82
9. Reiber GE, King H. Guidelines for the development of a national programme for diabetes mellitus. Geneva: World Health Organization, 1991
10. Klein R, Klein BEK, Moss SE. The epidemiology of ocular problems in diabetes mellitus. In: Feman SS, editor. Ocular problems in diabetes mellitus. Boston: Blackwell, 1992
11. Clark CM, Lee DA. Drug therapy: prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210-7
12. Marks HH, Krall LP. Onset, course, prognosis and mortality in diabetes mellitus. In: Marble A, editor. Joslin's diabetes mellitus. 11th ed. Philadelphia: Lea & Febiger, 1971: 209-54
13. World Health Organization. Report of a WHO Study Group. Geneva: World Health Organization, 1985 (WHO Technical Report Series)
14. Alberti KGMM, Gries FA, Jervell J, et al. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabetic Med 1994; 11: 899-909
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
16. Reichard P, Nilsson B-Y, Rosenqvist U, et al. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-9
17. Holman RR, Mayon-White V, Orde-Peckar C, et al. Prevention of deterioration of renal and sensory nerve function by more intensive management of insulin-dependent diabetic patients. A 2-year randomized prospective study. Lancet 1983; I: 204-8
18. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17
19. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-8
20. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1996; 19 Suppl. 1: S8-S15
21. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycaemia in the elderly patient with diabetes. Diabetes 1994; 43: 403-10
22. Anonymous. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1996; 19 Suppl. 1: S16-9
23. Anonymous. Foot care in patients with diabetes mellitus. Diabetes Care 1996 Jan; 19 Suppl. 1: 23-4
24. Facchini FS, Hollenbeck CB, Jeppeson J, et al. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-30
25. Watkins PJ. Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus. J R Coll Physicians Lond 1993 Jul; 27: 259-66
26. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
27. National Prescribing Centre. Non-insulin-dependent diabetes mellitus (part 2). MEREC Bulletin, National Health Service, Liverpool 1996; 29-32
28. Lebovitz HE. Oral hypoglycemic agents. In: Rifkin H, Porte Jr D, editors. Ellenberg & Rifkin's diabetes mellitus theory & practice. 4th ed. New York: Elsevier Science Publishing Co., 1990
29. Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46 (6): 1025-54
30. Tattersall RB, Scott AR. When to use insulin in the maturity onset diabetic. Postgrad Med J 1987; 63: 859-64
31. Hermann LS. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care 1990 Aug; 13 Suppl. 3: 37-41
32. DeFronzo R. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-9
33. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-depenedent diabetes mellitus. N Engl J Med 1995; 333: 550-4
34. Johnson AB, Webster JM, Sum C-F, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type-II diabetic patients. Metabolism 1993 Sep; 42: 1217-22
35. Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995; 11: S57-62
36. Hermann LS, Scherstén B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulfonylurea, alone and in primary combination. Diabetic Med 1994; 11: 953-60
37. Jeppeson J, Zhou M-Y, Chen Y-DI, et al. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994; 17: 1093-9
38. United Kingdom Prospective Diabetes Study Group. Prospective Diabetes Study (UKPDS): VIII. Study design, progress and performance. Diabetologia 1992; 34: 877-90
39. Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view. Diabetic Med 1988; 5: 275-81
40. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-41
41. Chalmers J, McBain AM, Brown IRF, et al. Metformin: is its use contraindicated in the elderly? Pract Diabetes 1992 Mar/Apr; 9: 51-3
42. Mooradian D, Kalis J, Nugent CA. The nutritional status of ambulatory elderly type II diabetic patients. Age 1990; 13: 87-9
43. Hermann LS, Scherstén B, Bitzén P-O, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994; 17: 1100-9
44. Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res 1985; 15 Suppl.: 105-11
45. Bristol-Myers Squibb Company. Metformin prescribing information. Princeton, New Jersey, 1995
46. Rubin RJ, Altman WM, Mendelson DN. Health care expenditure for people with diabetes, 1992. J Clin Endocrinol Metab 1994; 78: 809A-F
47. Rathmann W. Prescription drug use and costs among patients with diabetes mellitus. Pharmacoepidemiol Drug Saf 1996; 5 Suppl. 1: S20
48. Huse DM, Oster G, Killen MJ. The economic costs of non-insulin-dependent diabetes mellitus. JAMA 1989; 262: 2708-13